Regeneron Expects Mid-Teens R&D Expense Growth Rate in 2027
Photo: TokenPost
Regeneron Pharmaceuticals expects research and development expenses to rise at a mid-teens rate in 2027 compared with 2026, setting out a higher spending outlook on its third-quarter 2026 earnings call. The company also expects to recognize Sanofi’s $1 billion upfront payment in Q4. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
